Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is no 80mg dose of tirzepatide. The highest strength licensed in the UK is 15mg per weekly injection, and no regulatory authority — the MHRA, the FDA, or the EMA — has approved an 80mg formulation for any purpose. If you've seen 80mg tirzepatide advertised online, that's a serious red flag worth understanding before you go any further. The medicine is available in the UK only as Mounjaro, in six strengths from 2.5mg to 15mg, each requiring a prescription following clinical assessment by a registered prescriber. Tirzepatide's licensed strengths and how they work are covered in detail elsewhere on this site, but this page deals specifically with the 80mg question, because it comes up often and the answer matters.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro, the brand name for tirzepatide in the UK, is supplied as a pre-filled KwikPen. Each pen contains four weekly doses, and treatment always starts at 2.5mg, a lower, introductory strength chosen to let your body adjust before the dose moves upward. From there a prescriber titrates in 4-week steps: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and finally 15mg. That top dose is the ceiling. There is no 7.5mg-per-day version, no high-concentration vial, no 80mg anything. The NHS tirzepatide medicines page confirms the licensed strengths clearly.
Why does this matter practically? Because the numbers you find advertised on social media or certain websites often bear no resemblance to the real product. An 80mg figure could reflect a compounded (unlicensed) preparation, a counterfeit pen, or simply a made-up specification designed to look like a higher-potency bargain. None of those carry the safety data, manufacturing standards or MHRA oversight that Mounjaro does.
If you want to understand the difference between, say, the 60mg presentation (four pens at 15mg each, covering a month's supply at the top dose) and the starting options, those are real pack configurations, not dose strengths, a distinction that catches people out regularly.
Tirzepatide works as a dual GIP and GLP-1 receptor agonist, slowing gastric emptying and reducing appetite through two gut-hormone pathways simultaneously. Its effects are dose-dependent, which is precisely why the licensed schedule starts low and moves slowly. The clinical trial programme (SURMOUNT-1 involved 2,539 participants and ran for 72 weeks) tested specific doses with careful safety monitoring. At 15mg, average weight reduction reached around 20–21%. That evidence base covers 2.5mg through 15mg. It covers nothing above 15mg, because no rigorous human safety data exists for higher doses.
An 80mg single dose would represent more than five times the maximum licensed amount. Severe nausea, vomiting and dehydration would be expected consequences at minimum; the risks from unlicensed concentrations go further than that, particularly when the product's actual contents are unknown. A prescriber who reviewed your notes and recommended genuine Mounjaro is working from a framework of evidence. A seller offering 80mg has no such framework to offer you.
You can read about other pack configurations that appear in searches for context on how licensed supply is structured, the pattern there is consistent with what's described here.
The MHRA has warned publicly and repeatedly about fake weight-loss pens circulating through social media and unregistered websites. In October 2025, a manufacturing site producing counterfeit tirzepatide pens was raided in Northampton. Earlier enforcement actions found that some products labelled as weight-loss injections contained insulin instead, a dangerous substitution for someone who has not been assessed for diabetes.
Red flags for illegitimate supply include: products available without a prescription and without clinical assessment; dose strengths not matching the licensed schedule (80mg being one obvious example); prices dramatically below the UK private market; sellers with no GPhC registration. You can check any online pharmacy against the public register at the GPhC's pharmacy register, it takes about thirty seconds and costs nothing.
If you've already received a product and are unsure what it contains, contact your GP or 111. Suspected counterfeit medicines can be reported at the MHRA's Yellow Card scheme. That's genuinely useful information for the regulator, not just a bureaucratic step.
For a broader look at how cost fits into the choice of a legitimate provider, the Mounjaro cost context page covers what private treatment typically includes and what headline prices sometimes leave out.
If you found this page because you're trying to lose weight and wondering whether tirzepatide could help, that's a completely reasonable place to be. Many people searching for unusual doses are simply trying to find the most effective option, it's an understandable instinct, even if 80mg turns out not to exist. What does exist is a well-evidenced medicine, Mounjaro, licensed for adults with a BMI of 30 or above, or 27 and above with a weight-related health condition such as high blood pressure, high cholesterol or type 2 diabetes. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance.
The route to genuine tirzepatide is a prescription. At nume, a GPhC-registered Independent Prescriber reads every consultation personally (not software) and makes a clinical judgement the same day. Identity and weight are verified before anything is dispensed. If you want to understand the full picture of how licensed tirzepatide supply works from a regulated UK pharmacy, that's a reasonable next step. Or, if you're ready, you can check your eligibility through a free consultation with our prescribers.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.